Content validation of the SF-36v2® health survey with AL amyloidosis patients

Overview of attention for article published in Journal of Patient-Reported Outcomes, December 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

policy: 1 policy source

twitter: 5 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 17 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 5,870 followers.

RT @vsanchorawala: Future should focus on development of patient centric clinical trials with PROs as endpoints in AL amyloidosis. @BU_Amyl…

19 Jan 2023

Reply Repost Favourite

Future should focus on development of patient centric clinical trials with PROs as endpoints in AL amyloidosis. @BU_Amyloidosis 1) Content validity of SF-36 in AL amyloidosis https://t.co/XWVntRvHNa

19 Jan 2023

Reply Repost Favourite

RT @Taxkourel: SV36v2 as a tool to measure QoL related outcomes specifically for AL #amyloidosis patients https://t.co/qDBq02bPE5 @rmwarsame

22 May 2018

Reply Repost Favourite

SV36v2 as a tool to measure QoL related outcomes specifically for AL #amyloidosis patients https://t.co/qDBq02bPE5 @rmwarsame

22 May 2018

Reply Repost Favourite

RT @spencerdguthrie: I'm reading this on #springerlink https://t.co/KvSYFifgpF

04 Jan 2018

Reply Repost Favourite

I'm reading this on #springerlink https://t.co/KvSYFifgpF

04 Jan 2018

Reply Repost Favourite